CHIMERIX INC
- Headquarters
- DURHAM, NC
- Latest Form D
- $34.9M, Jul 2019
- Total capital
- $133M
- Federal grants
- $36.9M
- 7 awards · 2003–2004
- Private capital raised
- $96M
- 3 Form D · last Jul 2019
- 87 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 12
- 28 pending · first 2015
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$34.9M
- Private capital raisedForm D · SEC · 2nd filing$45M
- Private capital raisedForm D · SEC · 1st filing$16.1M
- Federal grantHealth and Human S · Phase I · Alkylglycero-PFA Analogs for Treating Drug Resistant HIV$300K
- Federal grantHealth and Human S · Phase I · Alkylglycero-PFA Analogs for Treating Drug Resistant HIV$300K
- Federal grantHealth and Human S · U01 · Development Of An Oral Drug For Smallpox Treatment$8.4M
- Federal grantHealth and Human S · U01 · Development Of An Oral Drug For Smallpox Treatment$3M
Show 3 earlier federal awards
- Federal grantHealth and Human S · U01 · Development Of An Oral Drug For Smallpox Treatment$7.7M
- Federal grantHealth and Human S · U01 · Development Of An Oral Drug For Smallpox Treatment$8.6M
- Federal grantHealth and Human S · U01 · Development Of An Oral Drug For Smallpox Treatment$8.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
71months
from CHIMERIX INC’s first federal award to its first private round.
- First federal award · Sep 2003
- Health and Human S · $8.5M
- First Form D · Aug 2009
- $16.1M · 1st Form D
- Awards before first raise
- 7 awards
An association in public records, not a cause or a prediction.
Founders and team
Researcher links verified by same-company patents and grants- Roy W. WareResearcherExecutive OfficerLinked by 1 patent
- Arthur M. PappasDirectorNamed in SEC Form D filings
- Catherine L. GillissDirectorNamed in SEC Form D filings
- Edward F. Greissing, Jr.DirectorNamed in SEC Form D filings
- Edward E. Penhoet, Ph.D.DirectorNamed in SEC Form D filings
- Farah P. ChampsiDirectorNamed in SEC Form D filings
Show all 29 people
- Fred A. MiddletonDirectorNamed in SEC Form D filings
- George I. Painter, Ph.DExecutive Officer, DirectorNamed in SEC Form D filings
- George Painter, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Graham K. Crooke, M.B.B.S.DirectorNamed in SEC Form D filings
- Gwendolyn P. Painter, M.D., MPHExecutive OfficerNamed in SEC Form D filings
- Heather W. Knight-TrentExecutive OfficerNamed in SEC Form D filings
- James M. DalyDirectorNamed in SEC Form D filings
- James M. NiedelDirectorNamed in SEC Form D filings
- Kenneth I. MochExecutive OfficerNamed in SEC Form D filings
- Martha J. DemskiDirectorNamed in SEC Form D filings
- Merrick Almond, Ph.D.Executive OfficerNamed in SEC Form D filings
- Michael A. AlrutzExecutive OfficerNamed in SEC Form D filings
- Mike AndrioleExecutive OfficerNamed in SEC Form D filings
- Mike ShermanExecutive Officer, DirectorNamed in SEC Form D filings
- Odin W. NadererExecutive OfficerNamed in SEC Form D filings
- Patrick F. MachadoDirectorNamed in SEC Form D filings
- Randall A. LanierExecutive OfficerNamed in SEC Form D filings
- Robert J. MeyerDirectorNamed in SEC Form D filings
- Ronald C. Renaud, JrDirectorNamed in SEC Form D filings
- Rosemary O'Mahony, Ph.D.Executive OfficerNamed in SEC Form D filings
- Seth A. Rudnick, M.D.DirectorNamed in SEC Form D filings
- Timothy J. WollaegerDirectorNamed in SEC Form D filings
- W. Garrett NicholsExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 12 granted of 40- PendingSolid State Forms Of Imipridone DerivativeUSPTOApplication 19219880
- PendingMORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOFUSPTOApplication 19027475
- Pending7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-one, Salts Thereof And Methods Of Using The Same In Combination TherapyUSPTOApplication 19079151
Show all 40 patent records
- Solid State Forms Of Imipridone DerivativeSep 10, 2026 · Application 19219880Pending
- MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOFDec 18, 2025 · Application 19027475Pending
- 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-one, Salts Thereof And Methods Of Using The Same In Combination TherapyJul 31, 2025 · Application 19079151Pending
- 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-a]PYRIDO[3,4-E] PYRIMIDIN-5 (1 H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPYApr 3, 2025 · Application 18979567Pending
- 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZ0[1,2-A]PYRID0[3,4-E] PYRIMIDIN-5 (1 H)-one, Analogs Thereof, And Salts Thereof And Methods For Their Use In TherapyAug 15, 2024 · Application 18603075Pending
- Uses And Methods For Recurrent Primary Cns NeoplasmsJul 18, 2024 · Application 18559992Pending
- 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZ0[1,2-A]PYRID0[3,4-E] PYRIMIDIN-5 (1 H)-one, Salts Thereof And Methods Of Using The Same In Combination TherapyJul 4, 2024 · Application 18429350Pending
- Pyrrolopyrimidine Nucleosides For Treating Or Preventing A SARS-COV-2 InfectionJun 27, 2024 · Application 18553144Pending
- MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOFJun 20, 2024 · Application 18354860Pending
- 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-a]PYRIDO[3,4-e]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPYMay 7, 2024 · US 11,976,068Granted
- MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOFJul 14, 2022 · Application 17393496Pending
- G Protein-coupled Receptor (gpcr) Modulation By ImipridonesMar 10, 2022 · Application 17388551Pending
- MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOFSep 7, 2021 · US 11,111,264Granted
- Morphic Forms Of Hexadecyloxypropyl-phosphonate Esters And Methods Of Synthesis ThereofJul 20, 2021 · US 11,066,373Granted
- Formulations Of BrincidofovirMay 7, 2020 · Application 16722699Pending
- Morphic Forms Of Hexadecyloxypropyl-phosphonate Esters And Methods Of Synthesis ThereofNov 26, 2019 · US 10,487,061Granted
- Morphic Forms Of Hexadecyloxypropyl-phosphonate Esters And Methods Of Synthesis ThereofOct 30, 2018 · US 10,112,909Granted
- Methods Of Treating Retroviral Infections And Related Dosage RegimesAug 2, 2018 · Application 15937999Pending
- Methods Of Treating Retroviral Infections And Related Dosage RegimesMay 1, 2018 · US 9,956,239Granted
- Morphic Forms Of Hexadecyloxypropyl-phosphonate Esters And Methods Of Synthesis ThereofJan 9, 2018 · US 9,862,687Granted
- Formulations Of BrincidofovirDec 28, 2017 · Application 15636393Pending
- Methods Of Treating Orthopox Virus Infections And Associated DiseasesNov 23, 2017 · Application 15669084Pending
- Nucleoside Phosphonate SaltsSep 19, 2017 · US 9,765,100Granted
- Methods Of Treating Retroviral Infections And Related Dosage RegimesJul 4, 2017 · US 9,694,024Granted
- Branched Chain Acyclic Nucleoside Phosphonate Esters And Methods Of Synthesis And Uses ThereofFeb 2, 2017 · Application 15101647Pending
- Methods Of Reducing Nephrotoxicity In Subjects Administered With Nucleoside PhosphonatesOct 20, 2016 · Application 15098011Pending
- Morphic Forms Of Hexadecyloxypropyl-phosphonate Esters And Methods Of Synthesis ThereofJun 21, 2016 · US 9,371,344Granted
- Phosphonate Ester Derivatives And Methods Of Synthesis ThereofApr 5, 2016 · US 9,303,051Granted
- Methods of Treating Viral Associated DiseasesMay 21, 2015 · Application 14542295Pending
- Method Of Mitigating Virus Associated End-organ DamageMar 26, 2015 · Application 14397471Pending
- Morphic Forms Of Hexadecyloxypropyl-phosphonate Esters And Methods Of Synthesis ThereofFeb 24, 2015 · US 8,962,829Granted
- Hexadecyloxypropyl Cidofovir For The Treatment Of Double-stranded Dna Virus InfectionOct 9, 2014 · Application 14354481Pending
- Compounds, Compositions and Methods for Treating Ocular ConditionsMay 1, 2014 · Application 14139294Pending
- Phosphonate Ester Derivatives and Methods of Synthesis ThereofFeb 13, 2014 · Application 14057391Pending
- Methods of Treating Retroviral Infections and Related Dosage RegimesJan 9, 2014 · Application 13934771Pending
- Uses Of Pyrrolopyrimidine Nucleosides And Analogs ThereofApplication 63308435Pending
- Formulations Of BrincidofovirApplication 62512825Pending
- Formulations Of BrincidofovirApplication 62507397Pending
- Formulations Of BrincidofovirApplication 62465053Pending
- Treatment Of Adenovirus With BrincidofovirApplication 62462522Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .